Share This Article:

Philadelphie chromosome—Positive de novo acute myeloid leukemia. Isolated meningeal relapse in a patient treated with imatinib mesylate

Abstract Full-Text HTML XML Download Download as PDF (Size:36KB) PP. 167-169
DOI: 10.4236/crcm.2013.22045    3,439 Downloads   4,730 Views   Citations

ABSTRACT

Acute myeloid leukemia philadelphie positive (Ph+ AML) is a rare aggressive acute leukemia with poor prognosis. We report a patient with ph positive AML (FAB5), the transcript bcr/abl was not performed at diagnosis. She achieved complete remission after conventional induction chemotherapy. The consolidation therapy was based on Imatinib only due to infectious complications. She was in complete hematologic and cytogenetic remission for 19 months, and after she exhibited an isolated meningeal relapse. A second remission was achieved with intrathecal chemotherapy and cranial irradiation. Imatinib was switched to second generation Tyrosine kinase Inhibitor which had better diffusion into cerebrospinal fluid. She is in complete hematologic, cytogenetic and meningeal remission after 14 months of treatment. Imatinib monotherapy affords insufficient protection from CNS relapse. Second generation Tyrosine kinase Inhibitor seems to have better efficiency. Ph+ AML with monoblastic differentiation should be considered, like Ph+ ALL, at high risk of meningeal leukemia and should receive central nervous system prophylaxis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Amor, I. , Mseddi, S. , Kassar, O. , Mnif, S. , Jdidi, I. , Mdhaffar, M. , Kammoun, L. , Bellaaj, H. , Saad, A. and Elloumi, M. (2013) Philadelphie chromosome—Positive de novo acute myeloid leukemia. Isolated meningeal relapse in a patient treated with imatinib mesylate. Case Reports in Clinical Medicine, 2, 167-169. doi: 10.4236/crcm.2013.22045.

References

[1] Soupir, C.P., Vergilio, J.A., Cin, P.D., et al. (2007) Philadelphia chromosome-positive acute myeloid leukemia: A rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. American Journal of Clinical Pathology, 127, 642-650. doi:10.1309/B4NVER1AJJ84CTUU
[2] Jentsch-Ullrich, K., Pelz, A.F., Braun, H., et al. (2004) Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica, 89, ECR15.
[3] Yamaguchi, M. and Konishi, I. (2003) Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia]. Rinsho Ketsueki, 44, 254-6.
[4] Leis, J.F., Stepan, D.E., Curtin, P.T., et al. (2001) Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL. Blood, 98, 140.
[5] Pfeifer, H., Wassmann, B., Hofmann, W.-K., et al. (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical Cancer Research, 9, 4674-4681.
[6] Takayama, N., Sato, N., O’Brien, S.G., et al. (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology, 119, 106-108. doi:10.1046/j.1365-2141.2002.03881.x
[7] Kondoa, T., Tasakab, T., Sanoa, F., et al. (2009) Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): A report with IM plasma concentration and bcr-abl transcripts. Leukemia Research, 33, e137-e138. doi:10.1016/j.leukres.2009.03.017
[8] Helenglass, G., Testa, J.R. and Schiffer, C.A. (1987) Philadelphia chromosome-positive acute leukemia: Morphologic and clinical correlations. American Journal of Hematology, 25, 311-324. doi:10.1002/ajh.2830250311
[9] van Dongen, J.J.M., Macintyre, E.A., Gabert, J.A., et al. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia, 13, 1901-1928. doi:10.1038/sj.leu.2401592
[10] Petzer, A.L., Gunsilius, E., Hayes, M., et al. (2002) Low concentrations of STI571 in the cerebrospinal fluid: A case report. British Journal of Haematology, 117, 623-625. doi:10.1046/j.1365-2141.2002.03523.x
[11] Dai, H., Marbach, P., Lemaire, M., et al. (2003) Distribution of STI-571 to the brain is limited by p-glycoprotein-mediated efflux. Journal of Pharmacology and Experimental Therapeutics, 304, 1085-1092. doi:10.1124/jpet.102.045260
[12] Patel, S.B., Gojo, I., Tidwell, M.L., Sausville, E.A., et al. (2011) Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma, 52, 1211-1214. doi:10.3109/10428194.2011.566950

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.